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Abstract
Cell competition is recognized to be instrumental to the dynamics and structure of the tumor-host interface in invasive
cancers. In mild competition scenarios, the healthy tissue and cancer cells can coexist. When the competition is
aggressive, competitive cells, the so called super-competitors, expand by killing other cells. Novel cytotoxic drugs and
molecularly targeted drugs are commonly administered as part of cancer therapy. Both types of drugs are susceptible
to various mechanisms of drug resistance, obstructing or preventing a successful outcome. In this paper, we develop a
cancer growth model that accounts for the competition between cancer cells and healthy cells. The model incorporates
resistance to both cytotoxic and targeted drugs. In both cases, the level of drug resistance is assumed to be a continuous
variable ranging from fully-sensitive to fully-resistant. Using our model we demonstrate that when the competition is
moderate, therapies using both drugs are more effective compared with single drug therapies. However, when cancer
cells are highly competitive, targeted drugs become more effective. In this case, therapies that are initiated with a
targeted drug and are exposed to it for a sufficiently long time are shown to have better outcomes. The results of the
study stress the importance of adjusting the therapy to the pre-treatment resistance levels. We conclude with a study
of the spatiotemporal propagation of drug resistance in a competitive setting, verifying that the same conclusions hold
in the spatially heterogeneous case.
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1. Introduction
Intra-tumor heterogeneity that results from both ge-
netic and non-genetic mechanisms has been receiving
increased attention in recent years (Gatenby and Gillies,
2008; Hanahan and Weinberg, 2011; Maley et al., 2017;
Marusyk et al., 2012; Merlo et al., 2006). Due to pheno-
typic and mutagenic diversity, cancer can be thought of
as an ecosystem formed by coexisting populations ex-
pressing abnormal features and different cell types that
are embedded in a heterogeneous habitat of normal tis-
sue (Hillen and Lewis, 2014). Accordingly, competi-
tion between tumor cells and healthy cells in the host
tissue may play a key role in cancer growth (Gil and
Rodriguez, 2016; Moreno, 2008). Although the mech-
anisms are complex and are not fully understood, it is
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known that cells can discriminate their types via short-
range interactions that quantify the relative expression
levels of particular proteins. Accordingly, cell com-
petition occurs in the process of identifying and elim-
inating the less fit cells. The fitness-induced process
generally eliminates the defective cells, such as Minute
gene mutated cells in D. melanogaster (Moreno et al.,
2002; Simpson, 1979). However, certain types of can-
cer cells can signal the death of their surrounding tis-
sue in a way that promotes their neoplastic transforma-
tion. After the “loser” cells disappear from the tissue,
the “winner” cells not only survive but also proliferate
to fill out the void created by the dying cells (Moreno,
2008). Figure 1 illustrates cancer growth in two distinct
competition scenarios.
To eliminate cancer cells and suppress their malig-
nant growth, various treatments are available, including
surgery, chemotherapy, immunotherapy, and radiother-
apy. In particular, cytotoxic chemotherapy and molec-
ular targeted approaches represent two modes of can-
cer treatment (Masui et al., 2013). Whereas chemother-
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Figure 1: Competition between healthy cells and cancer cells. Often
cancer cells and normal cells coexist and the expansion is restricted by
spatial competition (top). However, some cancer cells, the so called
super-competitors, expand by killing the healthy cells (bottom). Dia-
gram adapted from Moreno (2008).
apy uses highly potent chemicals to target dividing cells,
targeted drugs act on specific molecular targets that are
associated with cancer. Novel therapies and drug sub-
stances are constantly being developed (Ribeiro et al.,
2012).
For both chemotherapy and targeted therapy drug re-
sistance is the predominant factor limiting clinical suc-
cess (Gillet and Gottesman, 2010; Housman et al., 2014;
Masui et al., 2013; Teicher, 2006). For instance, resis-
tance to chemotherapy includes extrinsic mechanisms
that prevent the drug from reaching its target in an ac-
tive form due to short serum half-life or rapid clearance
by the kidneys and liver (Burris et al., 2011; Slinger-
land et al., 2012). Intrinsic cellular mechanisms involve
increased efflux or decreased uptake, enzymatic modi-
fication and inactivation of the drug, and alteration of
drug targets within the cell (Fodal et al., 2011; Gottes-
man, 2002; Gottesman et al., 2002). Resistance to tar-
geted drugs also relies on various mechanisms includ-
ing cellular responses that maintain the signaling de-
spite the effective targeting or signaling through alter-
ation of downstream effectors, and cell survival path-
ways by disabling apoptosis (Byers et al., 2013; Zhang
et al., 2012). Drug resistance involves genetic and epi-
genetic alternations that either exist prior to the treat-
ment or acquired, often induced by the drugs (Gillet
and Gottesman, 2010; Teicher, 2006). Clinical trials
of combinations of cytotoxic and targeted drugs suggest
that the complementing mechanisms can be used for de-
veloping effective therapies (Dorris et al., 2017; Ribeiro
et al., 2012).
Due to the complexity of the underlying mechanisms
and the multifactorial pathways of tumor growth and
drug resistance, various mathematical models have been
developed to describe and investigate the emergence
of cancer and its evolution. Modeling approaches in-
clude deterministic models using differential equations
(Anderson and Chaplain, 1998; Birkhead et al., 1987;
Tre´dan et al., 2007) and stochastic models including
branching process and multiple mutations for study-
ing multi-drug resistance and optimal control of drug
scheduling (Kimmel et al., 1998; Komarova, 2006; Mi-
chor et al., 2006). These modeling approaches have pro-
vided a framework for improving early detection, for
quantifying intrinsic and acquired resistance cells, and
for designing therapeutic protocols (Foo and Michor,
2014; Lavi et al., 2012; Michor et al., 2006; Roose et al.,
2007; Swierniak et al., 2009).
On top of that, various mathematical models incorpo-
rate tumor heterogeneity and competition between dis-
tinct cell types (Bacevic et al., 2017; Lorz et al., 2013;
Piretto et al., 2018; Yoon et al., 2018). Recent mod-
els using ordinary differentiation equations (ODEs) fo-
cus on competition between distinct types of cancer
cells that are either resistant or sensitive to a single
drug (Carre`re (2017); Piretto et al. (2018); Yoon et al.
(2018)). While ODEs can model the overall size of the
population, partial differential equations can model spa-
tial heterogeneity in either the physical space or in the
phenotypic space. Competition models using reaction-
diffusion equations date back to Gatenby and Gawlinski
(1996) that describe the spatial distribution and tempo-
ral evolution of an invasive tumor, accounting for the
density of the normal tissue and the neoplastic cancer-
ous tissue. Considering phenotypic heterogeneity, Lorz
et al. (2013) developed a model for the competition be-
tween healthy cells and tumor cells that depends on a
continuous phenotypic variable of cytotoxic drug resis-
tance level. All aforementioned models consider drug
resistance to a single drug.
To study the impact of cell competition and the het-
erogeneity in drug resistance, we develop a phenotypic
structured model extending the model proposed in Lorz
et al. (2013). Our model consists of healthy cells and tu-
mor cells depending on a continuous variable that repre-
sents the level of drug resistance. The model is aimed at
designing effective combination therapies (see also Cho
and Levy (2018b); Perthame et al. (2014)). We study
two scenarios: (i) a mild competition that allows coex-
istence of distinct cells; and (ii) an aggressive competi-
tion that results with the elimination of one population
(see Figure 1). We examine the tumor response under
a combination therapy of cytotoxic and targeted drugs,
assuming a continuous level of drug resistance to each
drug. This distinguishes our work from most other com-
petition models that only consider resistance to a single
drug (Bacevic et al., 2017; Carre`re, 2017; Lorz et al.,
2013). Our study implies that the optimal order between
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the drugs as well as the duration of therapy, depend on
the competition parameter and on the ratio of preexist-
ing resistant cells to each drug.
The paper is organized as follows. In section 2, we in-
troduce the competition model between cancer cell and
healthy cells with a multi-dimensional resistance trait.
We estimate the range of the competition rate that cor-
responds to the super-competitive scenario, where only
one population can survive. In section 3, we numer-
ically study our model, focusing on cancer growth and
on the emergence of resistance under different combina-
tion therapies. Therapies in which one drug is switched
for a second drug are compared to single-drug therapies
in section 3.1, particularly when the competition rate is
low. In section 3.2, we study the effect of different con-
tinuum models in the resistance space and numerically
compute the optimal switching time that minimizes the
overall number of cancer cells in a given time interval.
Alternating therapies and combination on-off therapies
are compared in section 3.3. The model is extended
to space and the proposed therapies are studied in sec-
tion 4. Concluding remarks are provided in section 5.
2. A Mathematical Model for the Competition Be-
tween Healthy Cells and Cancer Cells
To model the competition between healthy cells and
cancer cells and the emergence of resistance, we con-
sider two populations: healthy cells nh(t, θ) and cancer
cells nc(t, θ). Both populations describe the number of
cells at time t that have a resistance phenotype θ. The
variable θ = (θ1, θ2) ∈ [0, 1]2 describes the level of drug
resistance to cytotoxic drugs (θ1) and to targeted drugs
(θ2). The value 0 corresponds to full sensitivity to the
drug, and the value 1 corresponds to complete resis-
tance. For example, the level of resistance to cytotoxic
agents can be related to the expression level of a gene or
a gene cluster that is linked to the cellular level of drug
resistance and proliferation potential, such as MDR1,
ALDH1, CD44 (Amir et al., 2013; Hanahan and Wein-
berg, 2011; Medema, 2013). We model the competition
of nh(t, θ) and nc(t, θ) as a reaction-diffusion system,
∂tnh(t, θ) =
[
rh(θ) − dh(θ)(ρh(t)) − µh(θ)c1(t)] nh
− ahc(θ)ρc(t)nh + νh∆θnh, (1)
∂tnc(t, θ) =
[
rc(θ) − dc(θ)(achρh(t) + ρc(t)) − µc(θ)c1(t)
−ϕc(θ)c2(t)] nc − ach(θ)ρh(t)nc + νc∆θnc. (2)
The reaction terms involve proliferation, apoptosis, and
drug effect. The first reaction terms with r(θ) > 0
model the consumption of the resources depending on
the resistance level. We assume that the proliferation
rates satisfy ∂θi rh(θ) ≤ 0 and ∂θi rc(θ) ≤ 0, corre-
sponding to the assumption that resistant cells devote
their resources to developing and maintaining the drug
resistance mechanisms (see the experimental evidence
in Misale et al. (2015); Mumenthaler et al. (2015);
Wosikowski et al. (2000)).
The death terms involve the rate of apoptosis, dh(θ) >
0 and dc(θ) > 0. We consider a logistic growth model
with ρh(t) and ρc(t) being the total numbers of normal
cells and cancer cells, computed as
ρh(t) =
∫
nh(θ, t)dθ, ρc(t) =
∫
nc(θ, t)dθ,
and ρ(t) = ρh(t)+ρc(t). The carrying capacity of normal
cells with phenotype θ, is given by rh(θ)/dh(θ). Key to
the model are the competition terms: apoptosis due to
competition occurs with rates ahc and ach with respect
to the size of the other cell population. This resembles
the competitive Lotka–Volterra model, (e.g., Gatenby
and Gawlinski (1996); Murray (2002)), and has been
referred to as competition rate in competition models
(Piretto et al., 2018).
The drug effects that represent the death of can-
cer cells due to the action of cytotoxic and targeted
drugs are also included in the growth term. The time-
dependent dosages are denoted by c1(t) for the cyto-
toxic drug and c2(t) for the targeted drug. The healthy
cells are affected only by the cytotoxic drug with a drug
uptake function µh(θ). Cancer cells respond to both
the cytotoxic drug and to the targeted drug with uptake
functions µc(θ), and ϕc(θ), respectively. As the resis-
tance level increases, the cells become more resilient to
the drugs. This translates to the modeling assumption
∂θiµh(θ) ≤ 0, ∂θiµc(θ) ≤ 0, and ∂θiϕc(θ) ≤ 0 (Lorz et al.,
2015; Mumenthaler et al., 2015).
Chemotherapy uses highly potent chemicals that kill
rapidly dividing cells, thus we take µh(θ) > 0 and
µc(θ) > 0, and assume that the therapy is more effec-
tive with sensitive cells. On the other hand, targeted
therapies selectively target these cancer-related genetic
lesions. Hence, we let ϕc(θ) > 0, and assume that tar-
geted drugs do not affect healthy cells.
The Laplacian operator ∆θ =
∑n
i=1 ∂
2/∂θ2i describes
the instability in the resistance phenotypic space with
rates νh and νc. In addition to genetic mutations, epimu-
tations contribute to phenotypic instability: heritable
changes in gene expression that do not alter the DNA
(Brock et al., 2009; Glasspool et al., 2006; Gupta et al.,
2011). Recent experiments demonstrated that such non-
genetic instability and phenotypic variability allow can-
cer cells to reversibly transit between different phe-
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notypic states (Chang et al., 2006; Pisco et al., 2013;
Sharma et al., 2010).
2.1. Studying the competition parameter
Recent studies suggest that cell competition is of-
ten critical in shaping cancer development (Vivarelli
et al., 2012; Wagstaff et al., 2013). In particular, the
fitness-sensing process during competition that usually
eliminates defective cells, has a distinctive behavior in
pre-cancerous lesions (Moreno, 2008). By acquiring a
”super-fit” status, these super-competitors mutated cells
can sense the surrounding wild-type cells as ”less fit”
and signal the death of surrounding tissue that in turn
promotes their neoplastic transformation (Gil and Ro-
driguez, 2016). In our model, the competition parame-
ters ahc and ach describe the aggressiveness of the cells
towards cells from the other populations.
To characterize competition scenarios, we simplify
Eqs. (1)–(2) by excluding the diffusion terms, and con-
sider parameters as follows. We will revisit the diffusion
terms in a later section. The proliferation rate and death
rate are assumed to be constant. Cancer cells prolifer-
ate A times faster than healthy cells, that is, rH = r and
rC = Ar with A ≥ 1. The apoptosis rates are taken
as dH = dC = d. The cross-competition parameter is
taken as ahc = dha and ach = dca. We provide analyt-
ical results assuming that the model has a single trait
θ, so that ρh = nh and ρc = nc. This is of value since
phenotype-structured models are known to asymptoti-
cally converge to a Dirac-delta distribution at few dom-
inating resistance traits (Lorz et al., 2011; Perthame and
Barles, 2008). We consider the following scenarios:
• No treatment. When no drug is applied (c1 = c2 =
0), a nontrivial equilibrium of ρh > 0 and ρc > 0 exists
if r − d(ρh + aρc) = 0 and Ar − d(aρh + ρc) = 0. This
reduces to a condition that the two populations can co-
exist when the competition rate satisfies a ≤ 1/A. Oth-
erwise, when the competition rate is a > 1/A, one of
the cell populations must become extinct, either ρh > 0,
ρc = 0 or ρh = 0, ρc > 0. We consider this case as
the super-competitive scenario. Since A represents the
ratio of over-proliferation of cancer cells compared to
normal cells, for larger values of A, it is likely to be
super-competitive for a larger range of the competition
rate a.
Figure 2 shows healthy cells, cancer cells, and com-
bined counts, up to t = 40, for a = 0.0, 0.2, ... , 1.0.
We consider rh(θ) = r = 1.5 and rc(θ) = 2r = 3.0,
which corresponds to the relative proliferation A = 2
Healthy cells and cancer cells coexist when a < 1/2,
but when a > 1/2, the cancer cells overtakes the popu-
lation and the healthy cells are eliminated. This condi-
Figure 2: Comparison of the dynamics of the total number of cells
ρ(t) = ρh(t) + ρc(t) for different values of the competition parameter
a = 0, 0.2, ..., 1. The cancer cells proliferation factor is A = 2 and the
results are shown up to t = 40. Healthy cells and cancer cells coexist
when a ≤ 1/A = 0.5, while the cancer cells aggressively overtakes the
population when a > 0.5. The latter case corresponds to the super-
competitive model.
tion is demonstrated again in Figure 3(a). The relative
numbers of cells ρh(t)/ρ(t) and ρc(t)/ρ(t) at t = 50 are
plotted for different values of A and a. The coexistence
threshold 1/A is apparent in the results.
• Weak treatment. The condition for coexistence
changes when the drug is applied with small dosages.
For the cytotoxic drug, if c1 < min (r/µh, Ar/µc), then
coexistence amounts to a < (r − µhc1)/(Ar − µcc1). We
note that the condition is identical to the no treatment
case if the drug uptake rate of healthy cells versus can-
cer cells is proportional to the proliferation rate, that is,
if µc = Aµh. However, under weak targeted therapy,
c2 < r/ϕc, coexistence bois down to a < r/(Ar − Aϕcc2)
so that the cells are likely to coexist for larger values of
a.
• Strong treatment. We assume that the drug dosages
are sufficiently high such that only the most resistant
cells can survive, corresponding to θ∗ = 1, where θ∗ =
arg maxθ(r(θ) − µ(θ)c). With such a dosage c, the coex-
istence condition is identical to the no treatment case as
a ≤ 1/A.
The results shown in Figure 3(b,c) are computed with
A = 2 and agree with the theoretical thresholds. While
the cytotoxic drug does not change the range of a that
corresponds to coexistence, the targeted drug increases
the range of coexistence for weak dosages. The thresh-
old of the competition parameter is summarized in Ta-
ble 1.
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Figure 3: The relative size of healthy cells ρh(t)/ρ(t) (left) and cancer
cells ρc(t)/ρ(t) (right) at t = 50 depending on the competition param-
eter a. (a) Without the drug treatment, cells coexist when the competi-
tion parameter is a ≤ 1/A. The second and third rows show the results
for a fixed A = 2. (b) The competition trend does not change when
a cytotoxic drug is applied regardless of the dosage. (c) The targeted
drug has a significant impact on the dynamics of coexistence as it only
affects the cancer cells.
No drug, Weak drug
Strong drug Cytotoxic drug Targeted drug
a >
1
A
a >
r − µhc1
Ar − µcc1 a >
r
Ar − Aϕcc2
Table 1: The range of the competition parameter within 0 ≤ a ≤ 1
such that the competition model becomes aggressively competitive,
not allowing for coexistence. The competition is likely to be aggres-
sive when the over-proliferation ratio of the cancer cells A is large. We
note that the parameter range of the cytotoxic drug reduces to a > 1/A
for any dosage if µc = Aµh.
2.2. Effectiveness of targeted drugs in the highly com-
petitive case
Let us estimate the drug dosage based on the dom-
inating trait θ∗ = arg maxθ nc(θ). The instantaneous
growth rate at time t is
Gc = rc(θ∗) − dc(θ∗)(aρh(t) + ρc(t)).
This rate is reduced by µc(θ)c1(t) and ϕc(θ)c2(t) when a
drug is administered. We provide an estimation for the
case of rc(θ∗) = ηc/(1 + θ∗2) and µ¯c(θ∗) = µ¯c(1 − θ∗1),
assuming that an increased level of resistance implies
lower levels of proliferation and drug effect. For in-
stance, when the sensitive cells are dominant such that
θ∗1 ≈ 0, the growth rate without the treatment becomes
Gc ≈ ηc − d(θ∗)(aρh(t) + ρc(t)). This growth term for
the dominant cells is negative when the initial dosage of
cytotoxic drug satisfies
ηc
1+θ∗2 − d(θ∗)(aρh(t) + ρc(t))
µ¯c(1 − θ∗1)
< c1.
As θ∗1 increases, resistant cells arise. The cytotoxic drug
dosage that is necessary to lower the number of can-
cer cells increases and it may reach the maximum tol-
erated dose. Eventually, when θ∗1 ≈ 1, the drug effect
term, c1µ¯c(1 − θ∗1), becomes negligible even with high
dosages. In this case, reducing the growth rate using the
competition term involving the healthy cells becomes
more effective. Thus, when
ηc
1 + θ∗2
− c1µ¯c(1 − θ∗1) > 0,
targeted therapy is preferable since it can still suppress
the cancer cells using the competition term d(θ∗)aρh(t),
preserving the normal cells ρh(t) despite the reduced
drug effect due to resistance. The effect of this term
becomes more critical for larger values of the competi-
tion parameter a. We verify the effectiveness of targeted
drugs in the highly competitive case in our simulations.
2.3. Switching drugs as a function of the resistance ra-
tio
The choice of drug can be determined by consider-
ing the ratio of resistance. For simplicity we classify
the sensitive and resistant cancer cells into four groups
as ρS S , ρS R, ρRS , and ρRR, where S and R represent be-
ing sensitive and resistant to one of the drugs. The first
index corresponds to the cytotoxic drug and the sec-
ond index corresponds to the targeted drug. The treat-
ment type can be determined by comparing ρS R and ρRS ,
where the drug type with less resistant cells should be
administered first. For instance, if the resistant popula-
tion to the second drug is larger, ρS R > ρRS , it is more
effective to use the first drug, assuming that the effective
decay rates due to each drug, c˜1 and c˜2, are identical.
Since ρS R(e−c˜1t − 1) < ρRS (e−c˜2t − 1), we have
(ρS S + ρS R)e−c˜1t + (ρRS + ρRR) <
(ρS S + ρRS )e−c˜2t + (ρS R + ρRR),
where the left- and right-hand sides represent the num-
ber of cancer cells after treated for time t with the first
and the second drug, respectively. This result differs
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from the one obtained in Piretto et al. (2018), in which
a combination therapy of cytotoxic chemotherapy and
immunotherapy assuming resistance to only cytotoxic
drugs was considered. When cells that are resistant to
cytotoxic drugs are present, it was suggested to first ap-
ply the cytotoxic drug (Piretto et al., 2018).
3. Combining cytotoxic and targeted drugs
We study the effect of different combination therapies
with cytotoxic and targeted drugs. The resistance trait
becomes θ = (θ1, θ2) ∈ [0, 1]2, where θ1 and θ2 repre-
sents resistance to cytotoxic and targeted drug, respec-
tively. In particular, we consider the model functions as
in Lorz et al. (2013),
rh(θ) =
ηh∏2
i=1(1 + θ
2
i )
, rc(θ) =
ηc∏2
i=1(1 + θ
2
i )
, (3)
dh(θ) =
d∏2
i=1(1 − 0.1θi)
, dc(θ) =
d∏2
i=1(1 − 0.3θi)
,
where ηh = 1.5 and ηc = 3 are the maximum prolifera-
tion rates of healthy and cancer cells, respectively, and
d = 0.5 is the apoptosis rate. The drug uptake functions
are taken as
µh(θ) = 0.4(1 − θ1), µc(θ) = 0.8(1 − θ1),
ϕc(θ) = 0.8(1 − θ2). (4)
All model functions satisfy the positivity and slope as-
sumptions from section 2. The drug schedules we con-
sider are shown in Figure 4. We consider four different
therapies: (i) a single cytotoxic drug therapy initiated
at tc (a), that is, ci(t) = ci 1tc≤t; (ii) a switching therapy
such that the drug is switched once after ts (b), ci(t) =
ci 1tc≤t≤tc+ts and c j(t) = c j 1tc+ts≤t; (iii) an alternating
therapy with period tp (c), ci(t) = ci 1(2n)tp≤t−tc≤(2n+1)tp
and c j(t) = c j 1(2n−1)tp≤t−tc≤(2n)tp ; and (iv) combi-
nation on-off therapy with period tp (d), ci(t) =
ci 1(2n)tp≤t−tc≤(2n+1)tp and c j(t) = c j 1(2n)tp≤t−tc≤(2n+1)tp .
The initial cell populations are set as
nh(0, θ) =
1 − w
C0
exp
[
− (θ1 − µ1)
2

− (θ2 − µ2)
2

]
,
nc(0, θ) =
w
C0
exp
[
− (θ1 − µ1)
2

− (θ2 − µ2)
2

]
. (5)
Here, the mean resistance phenotype is centered at µ1
and at µ2 for the cytotoxic drug and the targeted drug,
respectively. In addition, w represents the initial propor-
tion of the cancer cells in the tissue, and  controls the
variance of the preexisting resistance. C0 is a normaliz-
ing constant chosen so that ρ(0) = 1.
0
Cytotoxic
Targeted
0
0 0
Figure 4: Drug scheduling considered in our simulations: (a) single
cytotoxic drug therapy initiated at tc; (b) drug switching therapy such
that the drug is switched once after ts; (c) alternating therapy with
period tp; and (d) on-off combination therapy with period tp. We also
test schedules of (a-c) initiated with targeted drugs.
3.1. Single drug and drug switching therapy using cy-
totoxic and targeted drugs
We first examine the outcome of a single drug ther-
apy for different values of the competition parameter a,
using either a cytotoxic or a targeted drug. We simulate
the model without the diffusion term (νh = νc = 0). For
the initial condition, we set µ1 = µ2 = 0, w = 10−5, and
 = 0.05. The results shown in Figure 5 confirm that the
competition parameter a determines the outcome: ei-
ther coexistence or aggressive competition. This is the
case with a low dosage ci = 1 as well as with a higher
dosage ci = 4. When a = 0.2, healthy cells and cancer
cells are both present throughout the treatment, but not
when a = 0.8. In particular, under a high dosage of the
cytotoxic drug, c1 = 4, the relapsed cancer cells over-
take the population. In the case of a targeted drug, the
healthy cells suppress the cancer cells for some time,
so that the relapse is delayed. This does not prevent
an eventual relapse. The results are consistent with the
observations of Suijkerbuijk et al. (2016) that showed
that when the APC mutant clones in Drosophila midgut
reach a certain size, they induce the apoptotic death of
the surrounding wild-type cells. From this simulation,
we observe that the targeted drug is partially effective in
the competitive scenario, a = 0.8.
Figures 6–7 show the effect of increasing the dosages
in the range 2 ≤ c ≤ 6 for the single drug therapy case,
comparing cytotoxic and targeted drugs. Here, we as-
sume less preexisting resistance by setting  = 0.02. In
Figure 6, acute relapse is observed under cytotoxic drug
with high dosages ci = 5, 6, where the number of cancer
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Figure 5: Comparison of the total number of cells ρ(t) = ρh(t) + ρc(t)
when using cytotoxic and targeted therapy with different values of the
competition parameter a = 0.2 and 0.8. The drug is administered at
tc = 10 with dosages ci = 1 and 4. When c1 = 4, administering a
cytotoxic drug results with a relapse regardless of the values of a. The
timing of the relapse is delayed in the case a = 0.8 when administering
a high dosage c2 = 4 of the targeted drug.
cells rapidly increases at later times (t > 50), compared
with moderate dosages (c = 2, 3). This is the case for
both competitive scenarios a = 0.2 and 0.8. However,
under targeted drugs, the relapse is worse when a = 0.2,
but not when the cells are highly competitive (a = 0.8).
The targeted drugs eliminate only the cancer cells which
helps the healthy tissue maintain its dominance and sup-
press the growth of cancer. In contrast, the cytotoxic
drug, provides an advantage to the highly proliferative
cancer cells, allowing them to fill in the void.
We compare the results when the rate of apoptosis
due to the cytotoxic drug is larger than the rate induced
by the targeted drug, hoping that this will provides in-
sights about improved drug scheduling. Figure 7 shows
the results where the uptake function of the cytotoxic
drug amplifies by up to 1.66 times the uptake function
Figure 6: Comparison of the total number of cancer cells ρc(t) for an
increased drug dosage 2 ≤ c ≤ 6. The results compare cytotoxic ther-
apy (up) and targeted therapy (down) for the competition parameters
a = 0.2 (left) and a = 0.8 (right). We observe that in general, high
cytotoxic drug dosages (c = 5, 6) result with a delayed, yet stronger
relapse compared with moderate dosages (c = 2, 3). In contrast, tar-
geted therapy results with a substantial delay in the relapse time in the
highly competitive case a = 0.8.
0 20 40 60 80 100
0
2
4
6
8
To
ta
l n
um
be
r o
f c
ell
s
0 20 40 60 80 100
0
2
4
6
8
0 20 40 60 80 100
0
2
4
6
8
To
ta
l n
um
be
r o
f c
an
ce
r c
ell
s
0 20 40 60 80 100
0
2
4
6
8
Figure 7: Comparison of the total number of cells, ρ(t) (top), and
cancer cells, ρc(t) (bottom), using cytotoxic and targeted therapy. The
uptake function of the cytotoxic drug is scaled such that it ranges from
100% to 166% of the uptake function of the targeted drug. The cy-
totoxic drug with a higher uptake reduces the cancer cells more ef-
fectively than the targeted drug until a certain time, especially when
a = 0.2. However, in the more competitive case, a = 0.8, the targeted
drug quickly becomes more effective.
of the targeted drugs. The cytotoxic drug with a stronger
uptake function is more efficient in killing the cancer
cells, until a certain time point where the resistant cells
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Figure 8: The total number of cells ρ(t) and cancer cells ρc(t) using
a combination therapy, switching the drug once. The initial drug is
applied at t = 10 and switched to the second drug at t = 20. In
the top 2 rows the cytotoxic drug is applied before the targeted drug.
The order is reversed in the bottom 2 rows. Switching the drug in
either way delays the relapse when a = 0.2. However, in the more
competitive case, a = 0.8, switching the targeted drug to a cytotoxic
drug with insufficient amount of drug (c1 = 4) results with a worse
outcome for the cancer cells.
cause a relapse. However, when a = 0.8, stronger apop-
tosis of the cytotoxic drug holds for a very short period
of time, so that the targeted drug has a significant advan-
tage over the cytotoxic drug. This suggests that there
may exist a drug scheduling that maximizes the drug
effect, particularly when the competition is less aggres-
sive (a = 0.2).
To demonstrate the effectiveness of combination ther-
apies, we compare the number of cells ρ(t) and ρc(t)
using a single drug therapy, to a combination therapy
switching either from a cytotoxic drug to a targeted
drug or the other way around. We comment that of-
ten the first-line therapy is replaced by other drugs once
it becomes ineffective (Biswas et al., 2016; Kalemke-
rian et al., 2012; Mok et al., 2009). Figure 8 presents
the results where the first drug is applied at t = 10, and
switched to the second drug at t = 20. We set the values
of the cytotoxic drug dosage, c1, and the targeted drug
dosage, c2, to either 4 or 6. We observe that switch-
ing the drug delays the relapse until the final simulation
time t = 80, in particular with the higher drug dosage,
ci = 6. While a single drug therapy eventually results in
a relapse due to the resistant population, we verify that
switching the drug helps in delaying the relapse. This
conclusion depends on the level of competition. With
a moderate dosage ci = 4, switching from a cytotoxic
drug to a targeted drug is effective when a = 0.2, but not
when a = 0.8, where targeted drugs are advantageous.
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Figure 9: Number of cancer cells when the treatment begins with the
cytotoxic drug at tc = 10, and then switches to the targeted drug at
different times (×). The targeted drug delays the relapse due to resis-
tance to the cytotoxic drug. In particular, when a = 0.2, there exists
a switching time that minimizes the number of cancer cells, approx-
imately tc + 20. However, in the more competitive case, a = 0.8, it
is better to switch the drugs earlier since the targeted drug is more
effective.
We further aim to compute the optimal switching
time. Figures 9 and 10 show the total number of can-
cer cells, ρc(t), for the low-competition (a = 0.2) and
the highly competitive (a = 0.8) cases. The drug is
switched at different times after the initial drug is ap-
plied at tc = 10. We fix the dosage as ci = 4. The
case when the therapy is initiated with a cytotoxic drug
is shown in Figure 9. We observe that the cancer cell
population remains low when the targeted drug is ap-
plied after the cytotoxic drug has eliminated sufficiently
many cells that were resistant to the targeted drug. The
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Figure 10: Number of cancer cells when the treatment begins with
the targeted drug at tc = 10, and then switches to the cytotoxic drug
at different times (×). The cytotoxic drug delays the relapse due to
targeted drug resistance when a = 0.2. Switching the drug at tc + 30
minimizes the total number of cancer cells. When a = 0.8, using
the targeted drug only without switching to a cytotoxic drug is more
effective.
second row shows the relative size of the total cancer
cell population compared to a single drug therapy, that
is,
∫ 80
0 ρc(t) dt
/∫ 80
0 ρ
∗
c(t) dt , where ρ
∗
c(t) is the number of
cancer cells subject ot a cytotoxic drug treatment only.
We observe that when a = 0.2, there exists an optimal
switching time. The relative cancer size is minimized to
20% when the therapy is switched at tc + 20. Figure 10
shows the opposite case where the drug is switched from
targeted to cytotoxic. Similarly, one can benefit from
switching the drug when a = 0.2. In this case, the op-
timal switching time is approximately tc + 30. When
a = 0.8, a therapy using only the targeted drug with a
dosage of c2 = 4 is more effective than an alternating
therapy. As a result, rapidly switching the drug from
targeted to cytotoxic yields significantly worse results,
while for the switching from cytotoxic to targeted drug
– the sooner the better.
3.2. Continuous phenotypic levels of drug resistance
In this section, we study the implications of con-
sidering a continuous resistant space on the treatment
scheduling. Generally, we will observe variations in the
mean resistant level as a function of the drug dosage.
In a previous work we demonstrated that different con-
tinuum models of proliferation and uptake functions
yield distinctive dynamics in the drug resistance space,
Cho and Levy (2018a). The dynamics of continuum-
resistance models can be similar to the dynamics of
models that are based on discrete levels of resistance.
It can also be significantly different. In linear models
of proliferation r(θ) and drug uptake µ(θ), the typical
outcome is that cells end up concentrating either in the
most sensitive or in the most resistant trait. Such dy-
namics is essentially similar to considering a model with
two resistance states: fully resistant and fully sensitive.
Differences between the continuum and discrete models
are observed with non-linear proliferation and drug up-
take functions. Here, we study how our model depends
on the choice of continuum models by considering two
functions: (i) a quadratic model that allows intermediate
resistance level,
rc(θ) = (ηc − ηc4 )
2∏
i=1
(1 − θ2i ) +
ηc
4
, µc(θ) = µ(θ1 − 1)2,
and (ii) a linear model for which the outcome is similar
to a discrete two-states model,
rc(θ) = (ηc − ηc4 )
2∏
i=1
(1 − θi) + ηc4 , µc(θ) = µ(θ1 − 1).
The parameters are taken to be comparable with
Eqs. (3)–(4). The death terms are assumed to be con-
stant, dh(θ) = dc(θ) = 0.5, and the epimutation rates are
set as νh = νc = 10−3.
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Figure 11: Distribution of healthy cells, nh(t, θ), and cancer cells,
nc(t, θ), in the resistance phenotype space using a quadratic model
and a = 0.2 for different drug dosages c = 1, 2, 3, 4 at t = 80. As
the drug dosage increases, the mean resistance level in cancer cells
gradually increases in the direction of θ1 or θ2 depending on the drug
type. Healthy cells are only affected by the cytotoxic drug.
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Figure 12: Distribution of healthy cells, nh(t, θ), and cancer cells,
nc(t, θ), in the resistance phenotype space using a linear model and
a = 0.2 for different drug dosages c = 1, 2, 3, 4 at t = 80. The level
of resistance in cancer cells changes from fully-sensitive, θi = 0, to
fully-resistant, θi = 1, depending on the drug dosage. This is a sharp
transition compared with the quadratic model in Figure 11.
Figures 11 and 12 show the distribution of both
healthy cells, nh(t, θ), and cancer cells, nc(t, θ), in the
resistance space. These results are computed with the
quadratic and linear models, while increasing the drug
dosage, c = 1, 2, 3, 4. The distributions are shown for
the case when the competition allows cells to coexist
(a = 0.2 at time t = 80). Figure 11 confirms that the
quadratic model allows for intermediate resistance lev-
els that gradually increase with increased drug dosage.
As the dosages of the cytotoxic and targeted drugs in-
crease, the mean resistance level of cancer cells nc(t, θ)
increases in the corresponding direction of θ1 and θ2.
The resistance levels of healthy cells is affected only by
the cytotoxic drug. In contrast to the smooth transition
in the resistance level observed in the quadratic model,
the outcome of the linear model is closer to binary as
shown in Figure 12. With the dosage threshold of c ≈ 3,
the dominating resistance trait instantly changes from
fully-sensitive (θi = 0) to fully-resistant (θi = 1). We
note that in the highly competitive case, a = 0.8, the dis-
tributions are similar to the results shown in Figures 11
and 12, only that the concentration of healthy cells is
relatively low, nh(t, θ) ≈ 0.
We proceed to studying the evolution of the distribu-
tion in the resistance space under drug switching ther-
apy. The results are shown in Figure 13. Here, the ini-
tial drug is applied at tc = 10 and is then switched to the
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Figure 13: Evolution of the cancer cell distribution nc(t, θ) at t =
10, 20, 30, 40 using the quadratic model (top) and the linear model
(bottom) with a drug switching therapy. The dosages satisfy c1 + c2 =
5. The initial drug is applied at t = 10, and the second drug is applied
at t = 20. In contrast to the single drug therapy, a combination therapy
reduces the levels of cancer cells that are resistant to one drug yet are
sensitive to the other drug.
second drug at t = 20. Prior to the treatment, the most
sensitive cells dominate the population. However, after
treatment is initiated, the resistant cells emerge, depend-
ing on the drug type. For instance, when the therapy is
switched from a cytotoxic drug to a targeted drug, the
distribution shifts from θ1  0 and θ2 = 0 to θ2  0.
Compared with the outcome of a single drug therapy,
the population of cancer cells that are resistant to one
drug and sensitive to the other drug declines. Cells that
are resistant to both drugs, θ1 ≈ 1 and θ2 ≈ 1, are likely
to survive.
Figure 14 compares the effect of switching therapy
to a single drug therapy for the two continuum mod-
els. The relative size of the total cancer cell popula-
tion compared with a single (cytotoxic) drug therapy,
is
∫ 100
10 ρc(t) dt
/∫ 100
10 ρ
∗
c(t) dt , where ρ
∗
c(t) is the number
of cancer cells under a cytotoxic drug treatment. Once
again, the results confirm that a single targeted drug
therapy is particularly effective when the cells are highly
competitive, a = 0.8. This is more significant in the lin-
ear model, where the relative size of the cancer cell pop-
ulation reduces approximately to 50%, compared with
80% with the quadratic model. When a = 0.2, the
switching therapy in any order is more effective than
the single drug therapies regardless of the continuum
model (ts ≥ 5). We note that the outcome of linear
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Figure 14: Relative number of cancer cells using drug switching ther-
apy compared to using a single cytotoxic drug for different values of
drug switching time ts. The results are shown for the quadratic model
(top) and the linear model (bottom). The linear model is more sensi-
tive to the switching time, and when a = 0.8, the outcome of a single
cytotoxic drug therapy or the switching therapy, can be worse than a
single targeted drug therapy, where the arrows indicate the increased
amount.
model strongly depends on the switching time ts, and
particularly becomes worse than the single targeted drug
therapy when a = 0.8, if the tumor is not exposed to the
targeted drug for a sufficiently long period.
3.3. Alternating therapies and on-off combination ther-
apies
In the previous sections we studied the emerging dy-
namics when switching cytotoxic and targeted drugs.
The study was performed assuming competition be-
tween healthy cells and cancer cells, and a continuum
resistance trait. In this section, we assume that the drug
can be changed within a short period of time, and study
the periodically alternating therapy and the on-off com-
bination schedules depicted in Figure 4(c,d). The re-
sults for these studies are shown in Figures 15–16. In
both figures, the drug therapies start at tc = 10. We test
for different dosages: (i) a moderate dosage c1 + c2 = 3
aiming at maintaining the cancer cell population at low
levels; and (ii) a high dosage, c1 + c2 = 5, aiming at
completely eliminating the cancer cells. We also test
for different competition rates a = 0.2 and 0.8. As a
reference, we plot the results obtained with single drug
therapy.
c 1
+
c 2
=
3
Figure 15: The number of cancer cells ρc(t) using different therapies
including single-drug, alternating, and combination therapy with a rel-
atively low dosage c1 + c2 = 3. The periods of alternating and com-
bination therapies are taken as tp = 2, 5, 8, and 12. The alternating
therapy in any order is more effective than others considering the over-
all number of cancer cells during the treatment. A shorter alternating
period (tp = 2) suppresses the cancer cells without oscillations. On
the other hand, the on-off combination therapy yields a highly oscilla-
tory outcome.
Figure 15 shows the dynamics of the cancer cells un-
der the moderate dosage. We observe that the alternat-
ing therapy is more effective than the other therapies, as
it reduces the overall number of cancer cells compared
to single drug therapies. In particular, alternating the
drug with a short period (tp = 2) suppresses the cancer
growth without oscillations. Initiating the alternating
therapy in any order ends with similar results for both
competition rates since the preexisting resistant popu-
lations to both drugs are identical. On the other hand,
the on-off combination therapy yields a highly oscilla-
tory behavior that results in larger numbers of cancer
cells during the off period compared with the single drug
therapy. Since the dosage of chemotherapy is restricted
due to its toxic nature (Dorris et al., 2017; Ribeiro et al.,
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c 1
+
c 2
=
5
Figure 16: The number of cancer cells ρc(t) using different therapies
including single-drug, alternating, and combination therapy with a rel-
atively high dosage c1 + c2 = 5, and period 2, 5, 8, 12. We observe
that alternating the drug as quickly as possible (tp = 2) delays the re-
lapse while suppressing the cancer cells. In case of a = 0.8, initiating
the therapy with the targeted drug is more effective than initiating it
with the cytotoxic drug. The on-off combination therapy also delays
the relapse effectively.
2012), the on-off combination therapy may not be effec-
tive in such situations.
In the case of a higher dosage, c1 + c2 = 5, we ob-
serve that the number of cancer cells reduces to less
than an order of magnitude for a certain time period be-
fore a relapse occurs. As shown in Figure 16, both of
the alternating and combination schedules significantly
delay the relapse compared to the single drug thera-
pies. As before, alternating the drug with shorter pe-
riods (tp = 2) keeps the cancer population below a cer-
tain threshold, in contrast to longer periods that may re-
sult in small peaks throughout the treatment. However,
when a = 0.8, we observe that initiating the therapy
with the targeted drug is more effective in the sense that
it overcomes the drawback of longer drug periods. We
also observe that the on-off combination therapy with a
high dosage effectively reduces the cancer cells popula-
tion and delays the relapse, similarly to the alternating
schedule with short periods. However, after the relapse,
the cancer cell population fluctuates more than with the
alternating schedule.
The results obtained so far assume equal sizes of pre-
existing populations that are resistant to the cytotoxic
and to the targeted drugs. However, since the preexist-
ing resistance is one of the critical factor in relapse, we
further study the more realistic scenario in which differ-
ent fractions of the pre-treatment population are resis-
tant to both drugs. We denote the number of cells that
are resistant to the cytotoxic drug and to the targeted
drug as
ρc,R1(t) =
∫
1θ1≥0.5
nc(t, θ)dθ, ρc,R2(t) =
∫
1θ2≥0.5
nc(t, θ)dθ,
respectively. We remark that the previous results corre-
spond to the case ρc,R1(0) = ρc,R2(0). We consider the
initial condition as in Eq. (5), but with different vari-
ances  = 0.02 or 0.08 for each direction, θ1 or θ2. The
ratio then either becomes ρc,R1(0) : ρc,R2(0) = 1 : 104 or
ρc,R1(0) : ρc,R2(0) = 104 : 1.
Figure 17 presents the results for the case when the
cytotoxic resistant cells have a higher ratio, that is,
ρc,R1(0) > ρc,R2(0). Figure 18 shows the opposite case.
We test the same therapies as before including the sin-
gle drug, alternating therapies, and combination thera-
pies. We consider the moderate dosage c1 + c2 = 3
and the high dosage c1 + c2 = 5. The competition rates
are set as a = 0.2 and 0.8. Similar conclusions hold
as in the symmetric pre-treatment case. With a rela-
tively low dosage, the alternating schedule with a small
period works remarkably better than the combination
therapy, while with a relatively high dosage, the com-
bination therapy can also suppress the tumor growth for
a certain period of time. However, in the asymmetric
pre-treatment case, the order of drugs becomes more
important to the therapy outcome. First, the outcome
of single drug therapy is correlated with the size of the
preexisting resistance: In Figure 17, the cytotoxic drug
produces a worse outcome due to a larger pre-treatment
resistance population, while the targeted drug yields the
early relapse portrayed in Figure 18. In addition, when
ρc,R1(0) > ρc,R2(0), initiating an alternating schedule
with a targeted drug is more effective than initiating it
with the cytotoxic drug, particularly for higher dosages.
Clearly, this is the outcome because the targeted drug
reduces the population of cells that are resistant to the
cytotoxic drug. In addition, for the highly competitive
case, a = 0.8, we observe that a single targeted drug
therapy with dosage c1 + c2 = 3 yields the minimal
number of cancer cells up to t ≈ 40 with a relatively
low dosage. This provides us with an opportunity to
design an effective adaptive therapy.
On the other hand, when ρc,R1(0) < ρc,R2(0), it is
better to initiate the treatment with the cytotoxic drug.
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c 1
+
c 2
=
3
c 1
+
c 2
=
5
Figure 17: Number of cancer cells ρc(t) for different therapies when
the number of cells that are resistant to the cytotoxic drug is larger
than those that are resistant to the targeted drug (ρc,R1 > ρc,R2). We
observe that initiating the alternating therapy with the targeted drug
with a smaller resistant population is more effective.
As expected, the results suggest that the pretreatment
drug resistance can be a critical factor in determining
the coure of therapy and its outcome.
c 1
+
c 2
=
3
c 1
+
c 2
=
5
Figure 18: Number of cancer cells ρc(t) for different therapies when
the number of cells that are resistant to the targeted drug is larger than
those that are resistant to the cytotoxic drug (ρc,R1 < ρc,R2). In contrast
to Figure 17, initiating the alternating therapy with the cytotoxic drug
is more effective.
In addition to drug scheduling, we also study the ef-
fect of dosages with respect to asymmetric preexisting
resistance. In Figure 19, we present the number of can-
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cer cells ρc(t) at t = 100 using a combination therapy
with a cytotoxic drug dosage c1 and a targeted drug
dosage c2. When ρc,R1 > ρc,R2, we observe that a higher
dosage of the targeted drug is more effective than in-
creasing the dosage of the cytotoxic drug. For instance,
the dosage (c1, c2) = (2, 3) results in a smaller tumor
than (c1, c2) = (3, 2). In the opposite case, ρc,R1 < ρc,R2,
the result is reversed: c1 < c2 is a more effective treat-
ment. When the competition is mild, a = 0.2, increasing
the dosages of both drugs constantly improves the out-
come. However in the highly competitive case, a = 0.8,
there exists an optimal dosage of the cytotoxic drug. For
instance, when ρc,R1 > ρc,R2, (c1, c2) = (1.5, 3) results
with the minimum number of cancer cells. The opti-
mal dosage changes to (c1, c2) = (2.5, 3), with a slightly
larger cytotoxic drug dosage when ρc,R1 < ρc,R2.
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Figure 19: Number of cancer cells at time t = 100, ρc(100), for differ-
ent dosages of combination therapy involving cytotoxic and targeted
drugs. The results are tested for different sizes of pre-existing resis-
tance either ρc,R1 < ρc,R2 or ρc,R1 > ρc,R2. As expected, initiating the
switching therapy with the drug that has a smaller resistant population
is more effective. When a = 0.8, there exists an optimal dosage of the
cytotoxic drug.
4. Tumor growth model with cell competition
We extend the competition model by including a
physical space variable x ∈ [−1, 1]2 ⊂ R2. The con-
centrations of healthy cells, nh(t, x, θ), and cancer cells,
nc(t, x, θ), are governed by the following system,
∂tnh(t, x, θ) = GHnh + νn∆xnh + νp∇x · (nh∇x ph), (6)
∂tnc(t, x, θ) = GCnc + νn∆xnc + νp∇x · (nc∇x pc).
Here, ph(t, x) = (ρh/ρh,0)k and pc(t, x) = (ρc/ρc,0)k, are
the cell pressures for the healthy cells and the cancer
cells, respectively. The normalizing constants are taken
as the maximum cell capacity ρh,0 = 3 and ρc,0 = 6. The
growth terms, GH and GC , are taken as in Eqs. (1) and
(2), and νn and νp are constants describing cell motility.
The spatial competition model follows the tumor growth
model developed in Cho and Levy (2018b), and the cell
motility parameters are taken as νh = νc = 10−6, νp =
10−5, and k = 6 (Bray, 2000).
We consider three spatially heterogeneous drug dis-
tributions to examine the therapies c1(t, x) and c2(t, x):
i. A constant dosage,
ci(t, x) = c¯i(t).
ii. A diffusive case, where the drug diffuses from the
right edge x1 = 1 (Mumenthaler et al., 2015),
ci(t, x) = c¯i(t)
[
(eλ(x1+1)/2 + e−λ(x1+1)/2)/(eλ + e−λ)
]
,
with λ =
√
2.
iii. A highly heterogeneous case (Peng et al., 2016),
ci(t, x) = c¯i(t)
[
2 + 0.25 sin(2pi ‖ (x1 + 1, x2 + 1) ‖2)
+ 0.5 sin(4pi ‖ (1 − x1, x2 + 1) ‖2)
]
/2.75.
We assume a similar dependence of the resources on
the space variable, ηh(x) and ηc(x), with all three cases
considered. We choose the initial condition as a small
concentration of cancer cells embedded in the center of
a healthy tissue (see Figure 20, t = 0). The follow-
ing results are presented by plotting the total number of
healthy cells, ρh(t, x, y) =
∫
nh(t, x, y, θ)dθ, and cancer
cells, ρc(t, x, y) =
∫
nc(t, x, y, θ)dθ.
Figure 20 corresponds to the case of a constant
dosage. The initial tumor is located at the center of
the domain. The first row shows the mildly compet-
itive case, a = 0.2, and treatment with the cytotoxic
drug. The second row shows the highly competitive
case, a = 0.8, and treatment with the targeted drug.
The treatments are initiated at tc = 6 and tc = 10, re-
spectively, with dosages c¯1 = c¯2 = 5. We observe that
the cytotoxic therapy eliminates the healthy tissue in ad-
dition to the cancer cells, unlike the targeted drug. In
addition, when a = 0.2, the cancer cells grow on top
of the healthy tissue, while in the highly competitive
case, a = 0.8, the cancer cells replace the healthy tissue
while expanding. In both cases, a tumor treated with a
single drug therapy quickly relapses due to the preexist-
ing resistant cells. The spatial simulations with constant
dosages are consistent with the results of the non-spatial
model in the previous sections.
We now test combination therapies when the drug
distribution is spatially heterogeneous. Figure 21 com-
pares single drug therapies and alternating therapies
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Figure 20: The evolution of cancer cells ρc(t, x, y) and healthy cells
ρh(t, x, y) under single-drug therapies initiated with a small cancer
population in the center of the domain (left, t = 0). The cancer cells
grow on top of the healthy tissue when a = 0.2 (top, t = 6). When
a = 0.8 (bottom, t = 10), the cancer cells aggressively eliminate the
healthy cells while expanding. The treatment starts at t = 6 (top) and
t = 10 (bottom). The cancer cells relapse quickly when using a single
drug therapy due to preexisting resistance.
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Figure 21: The evolution of cancer cells ρc(t, x, y) and healthy cells
ρh(t, x, y) under single-drug and alternating (Alt.) therapies diffused
from the right boundary, x = 1. When a = 0.2, the alternating therapy
is remarkably effective compared with a single cytotoxic drug. When
a = 0.8, a single targeted drug therapy is also effective, although the
tumor size is slightly larger compared with the tumor size with the
alternating therapy.
with period tp = 2, when the resource and drugs are
diffused from the right boundary, x1 = 1. The treatment
dosages are taken as c¯1 = 7 and c¯2 = 4. We remark that
prior to the treatment, the tumor grows faster closer to
the right boundary where the concentration of resources
is high. Using a single drug therapy, the tumor relapses
before t = 40, particularly when a = 0.2 using the cy-
totoxic drug. When a = 0.8, we verify the effectiveness
of the targeted drug, for which we observe that the size
of the tumor at t = 40 is smaller compared with the tu-
mor at the same time using the cytotoxic drug, despite
the lower drug dosage. The alternating therapies are
more effective compared with the single-drug therapies
in all competition environments, although the difference
is smaller in the highly competitive case a = 0.8, since
the single targeted drug therapy is effective as well.
Finally, different therapies including the on-off com-
bination therapies are compared in Figure 22. We set
the dosages as c¯1 = c¯2 = 5, which are sufficiently high
so that the on-off combination therapies are effective as
much as the alternating therapies. The drug distribution
is heterogeneous. As expected, the single drug therapies
result with strong relapses compared with the alternat-
ing and combination therapies. In addition, we observe
emerging local peaks of cancer cells when using com-
bination therapies during the off periods. This is partic-
ularly worse than the outcome of alternating therapies
when a = 0.2. In case of a = 0.8, although the alternat-
ing therapy is more effective in suppressing the tumor
throughout the treatment than the combination therapy,
the sizes of the relapsed tumors at t = 40 are similar.
5. Conclusion
In this work we develop a competition model of
healthy and cancer cells that takes into account resis-
tance to cytotoxic and targeted drugs. We study the dy-
namics of resistance to the drugs and observe the emer-
gence of populations with distinct levels of resistance
depending on the therapy. Primarily, we classify the
cell competition scenarios as either mild, where distinct
cell types can coexist, or aggressive, where cancer cells
dominate by actively eliminating the healthy cells. The
threshold of the competition rate that distinguishes the
two scenarios is related to the over-proliferation of the
cancer cells over the healthy tissue. It also depends on
the drug dosages. In addition, the analysis shows that
targeted therapies have a greater potential of being ef-
fective when the cells are highly competitive.
Various drug treatments are tested in the two com-
petition scenarios, and we observe that the treatment
outcomes are distinctive. Although the targeted drug
is more effective in the highly competitive case, using
a single drug therapy, either cytotoxic or targeted, re-
sults with an eventual relapse due to the preexisting re-
sistance, regardless of the strength of the competition.
However, treatments that include both drugs show bet-
ter outcomes in terms of the relapse time and the tumor
size. Considering the drug switching therapy, an opti-
mal switching time that minimizes the overall number
of cancer cells exists when the competition is mild. In
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Figure 22: The evolution of cancer cells ρc(t, x, y) and healthy cells
ρh(t, x, y) under different therapies with an irregular drug distribution.
Local peaks of cancer cells can be observed that eventually grows
into a tumor with a rough surface. The single-drug therapies result in
strong relapses compared with the outcomes of alternating (Alt.) and
combination (Comb.) therapies. Moreover, the alternating therapy is
more effective than the on-off combination therapy particularly when
a = 0.2.
the highly competitive case, the targeted drug therapy
alone is often effective enough. We also compare differ-
ent continuum models that either allow for intermediate
resistance states or are close to a two-state model with
cells that are either fully sensitive or fully resistant to the
drugs. Although the overall advantage of the switching
therapy over single drug therapy in different competi-
tion environment holds, the linear model is shown to be
more sensitive to the switching time that often yields
a worse outcome compared with a single targeted drug
therapy. Thus, when the population is highly compet-
itive and the tumor proliferation and the drug uptake
linearly depend on the resistance trait, the drug switch-
ing time should be more carefully determined. Alter-
nating treatments with different periods are shown to
be effective in suppressing the cancer population during
the entire treatment period compared to the other thera-
pies. This particularly holds with small periods. Finally,
we investigate a spatially heterogeneous tumor growth
model, and verify that the same conclusions hold.
As future work, we propose to incorporate experi-
mental results considering combination of chemother-
apy and targeted therapies (Dorris et al., 2017; Ribeiro
et al., 2012) and develop optimal strategies using opti-
mal control theory for stabilizing the cancer population
and/or minimizing the tumor size during the treatment
period (Carre`re, 2017; Jonsson et al., 2017). Adaptive
therapy is another interesting topic that aims at control-
ling the tumor by maintaining sensitive cells in order to
suppress the resistant cancer cells (Bacevic et al., 2017;
Gatenby et al., 2009). Finally, the computational cost
of simulating three-dimensional tumor growth models
with multi-dimensional resistance traits is prohibitively
expensive due to the high dimensionality. This re-
quires developing an efficient numerical method that
balances computational cost and accuracy (Cho et al.,
2016; Grasedyck et al., 2013).
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